Starpharma Holdings Limited SPHRY Stock
Starpharma Holdings Limited Price Chart
Starpharma Holdings Limited SPHRY Financial and Trading Overview
| Starpharma Holdings Limited stock price | 0.59 USD |
| Previous Close | 2.55 USD |
| Open | 2.6 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 2.6 - 2.6 USD |
| 52 Week Range | 2.48 - 5.77 USD |
| Volume | 525 USD |
| Avg. Volume | 411 USD |
| Market Cap | 106.73M USD |
| Beta (5Y Monthly) | 0.863218 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
SPHRY Valuation Measures
| Enterprise Value | 68.07M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 22.587975 |
| Price/Book (mrq) | 2.6 |
| Enterprise Value/Revenue | 14.406 |
| Enterprise Value/EBITDA | -4.342 |
Trading Information
Starpharma Holdings Limited Stock Price History
| Beta (5Y Monthly) | 0.863218 |
| 52-Week Change | -44.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.77 USD |
| 52 Week Low | 2.48 USD |
| 50-Day Moving Average | 2.98 USD |
| 200-Day Moving Average | 3.57 USD |
SPHRY Share Statistics
| Avg. Volume (3 month) | 411 USD |
| Avg. Daily Volume (10-Days) | 290 USD |
| Shares Outstanding | 41.05M |
| Float | 38.21M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -340.44% |
| Gross Margin | -184.23% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.089% |
| Return on Equity (ttm) | -33.26% |
Income Statement
| Revenue (ttm) | 4.73M USD |
| Revenue Per Share (ttm) | 0.12 USD |
| Quarterly Revenue Growth (yoy) | -21.39% |
| Gross Profit (ttm) | -9294000 USD |
| EBITDA | -15675000 USD |
| Net Income Avi to Common (ttm) | -15982000 USD |
| Diluted EPS (ttm) | -0.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 44.04M USD |
| Total Cash Per Share (mrq) | 1.08 USD |
| Total Debt (mrq) | 7.85M USD |
| Total Debt/Equity (mrq) | 19.13 USD |
| Current Ratio (mrq) | 3.895 |
| Book Value Per Share (mrq) | 1 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6998000 USD |
| Levered Free Cash Flow (ttm) | -1936750 USD |
Profile of Starpharma Holdings Limited
| Country | United States |
| State | VIC |
| City | Abbotsford |
| Address | 4-6 Southampton Crescent |
| ZIP | 3067 |
| Phone | 61 3 8532 2700 |
| Website | https://starpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 50 |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Q&A For Starpharma Holdings Limited Stock
What is a current SPHRY stock price?
Starpharma Holdings Limited SPHRY stock price today per share is 0.59 USD.
How to purchase Starpharma Holdings Limited stock?
You can buy SPHRY shares on the OTC Markets OTCQX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Starpharma Holdings Limited?
The stock symbol or ticker of Starpharma Holdings Limited is SPHRY.
Which industry does the Starpharma Holdings Limited company belong to?
The Starpharma Holdings Limited industry is Biotechnology.
How many shares does Starpharma Holdings Limited have in circulation?
The max supply of Starpharma Holdings Limited shares is 41.81M.
What is Starpharma Holdings Limited Price to Earnings Ratio (PE Ratio)?
Starpharma Holdings Limited PE Ratio is now.
What was Starpharma Holdings Limited earnings per share over the trailing 12 months (TTM)?
Starpharma Holdings Limited EPS is -0.19 USD over the trailing 12 months.
Which sector does the Starpharma Holdings Limited company belong to?
The Starpharma Holdings Limited sector is Healthcare.